Trials / Sponsors / Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc.
Industry · 6 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | BP1001-A in Patients With Advanced or Recurrent Solid Tumors Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms | Phase 1 | 2022-08-19 |
| Recruiting | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | 2022-08-16 |
| Active Not Recruiting | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) | Phase 1 | 2020-11-05 |
| Withdrawn | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | 2017-09-01 |
| Recruiting | Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML Acute Myeloid Leukemia (AML) | Phase 2 | 2016-05-01 |
| Completed | Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome | Phase 1 | 2010-06-01 |